Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details)

v3.24.2.u1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
12 Months Ended
May 31, 2024
May 31, 2023
Summary Of Significant Accounting Policies    
Net Income (Loss) $ (49,841) $ (79,824)
Accumulated deficit (891,531) (841,690)
Balance in excess of federally insured limits 2,900 2,300
Restricted cash, uninsured amount 6,700 5,500
Restricted cash 6,704 6,507
Inventories, net $ 0 $ 0
Extended shelf life 4 years  
Bulk Drug Substance    
Summary Of Significant Accounting Policies    
Shelf life 4 years